Abliva
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
ABLI | ST
Overview
Corporate Details
- ISIN(s):
- SE0002575340
- LEI:
- 5493005YV22OTMUHZ183
- Country:
- Sweden
- Address:
- Medicon Village, 223 81 Lund
- Website:
- https://abliva.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Abliva is a clinical-stage biotechnology company that develops medicines for the treatment of primary mitochondrial diseases. These rare, congenital, and often severe conditions occur when the cell's ability to convert energy is impaired. The company is focused on discovering and developing therapies to restore mitochondrial function and improve the lives of patients. Its portfolio includes the lead drug candidate KL1333, which is being evaluated in the FALCON Phase II clinical study for adult patients with primary mitochondrial disease. Abliva aims to be a leader in the field of mitochondrial medicine.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-03 13:10 |
Delisting Announcement
Delisting of the shares of Abliva: last day of trading 17 March 2025
|
English | 64.3 KB | ||
| 2025-03-03 13:10 |
Delisting Announcement
Avnotering av aktierna i Abliva: sista handelsdag 17 mars 2025
|
Swedish | 64.1 KB | ||
| 2025-02-26 08:30 |
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting in Abliva AB (publ)
|
English | 74.8 KB | ||
| 2025-02-26 08:30 |
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Abliva AB (publ)
|
Swedish | 75.2 KB | ||
| 2025-02-25 09:50 |
Delisting Announcement
Abliva applies for delisting and will convene an extraordinary general meeting
|
English | 64.9 KB | ||
| 2025-02-25 09:50 |
Delisting Announcement
Abliva ansöker om avnotering och kommer att kalla till extra bolagsstämma
|
Swedish | 65.1 KB | ||
| 2025-02-21 14:41 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.6 KB | ||
| 2025-02-21 08:30 |
Annual Report
|
Swedish | 2.6 MB | ||
| 2025-02-21 08:30 |
Annual Report
|
English | 2.6 MB | ||
| 2025-02-12 11:37 |
Major Shareholding Notification
|
Swedish | 9.5 KB | ||
| 2025-02-11 15:52 |
Major Shareholding Notification
|
Swedish | 9.7 KB | ||
| 2024-12-15 20:00 |
M&A Activity
Uttalande från Ablivas styrelse med anledning av Pharmings kontanta offentliga …
|
Swedish | 83.3 KB | ||
| 2024-12-15 20:00 |
M&A Activity
Statement by the Board of Directors of Abliva regarding the public cash offer f…
|
English | 80.9 KB | ||
| 2024-11-29 18:00 |
Quarterly Report
|
Swedish | 2.9 MB | ||
| 2024-11-29 18:00 |
Quarterly Report
|
English | 2.9 MB |
Automate Your Workflow. Get a real-time feed of all Abliva filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Abliva
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Abliva via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-07 | David Bejker | Other | Sell | 269,005 | 121,052.25 SEK |
| 2024-05-31 | Catharina Janzon Johansson | Other | Other | 2,000,000 | 60,000.00 SEK |
| 2024-05-28 | David Laskow-Pooley | Other | Other | 1,000,000 | 30,000.00 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 54,128 | 11,664.58 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 38,000 | 8,151.00 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 36,064 | 7,807.86 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 15,091 | 3,267.20 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,901 | 2,588.47 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,270 | 2,479.40 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,275 | 2,474.86 SEK |
Peer Companies
